Oncology

Molecular Methodologies & Technologies

Utilization of Cell Free DNA in Characterization and Detection of Minimal Residual Disease in Lymphoid Malignancies

Program Committee Moderator(s)

• 

  Craig Soderquist, MD

  Assistant Professor
  Columbia University
  New York, New York, United States

Co-Moderator (Early Career)(s)

• 

  Zejuan Li, MD, PhD, FACMG

  Associate Professor
  Pathology and Genomic Medicine
  Houston Methodist Hospital
  Houston, Texas, United States

Session

Description: Measurable residual disease (MRD) detection is becoming increasingly important in prognostication and management of B-cell lymphomas. Cell-free DNA (cfDNA) offers a promising non-invasive avenue for assessing MRD. While prior MRD techniques primarily focused on immunoglobulin gene sequencing, newer cutting-edge methodologies, including Phased-Seq and CAPP-Seq, offer superior sensitivity and specificity in MRD analysis. This session will focus on the latest advancements in MRD analysis with a focus on the technical aspects, as well as some of the practical consideration for implementation of these techniques in a clinical laboratory.

If this session topic is of interest to you, please consider looking at the following course on AMP EDucation (AMPED™ Online)

Title: Opportunities & Challenges toward the Clinical Application of ctDNA MRD Testing in Solid Cancers
Click here to learn more.

Presentations:

• 10:15 AM – 11:00 AM PST

  cfDNA in Early Detection of Hematologic malignancies
  

  Breakout Speaker: Rita Shaknovich, MD, PhD – Shaknovich Consulting LLC
• 11:00 AM – 11:45 AM PST

  Profiling Cell-Free DNA in Lymphoma: MRD and Beyond
  

  Breakout Speaker: Brian Sworder, MD, PhD (he/him/his) – University of California, Irvine